Factors associated with length of stay following trans-catheter aortic valve replacement - a multicenter study

Yaron Arbel1,2, Nevena Zivkovic1,2, Dhruven Mehta1,2, Sam Radhakrishnan1,2, Stephen E. Fremes1,2, Effat Rezaei2,5, Asim N. Cheema2,5, Sami Al-Nasser2,5, Ariel Finkelstein6 and Harindra C. Wijeysundera1,2,3,4*

Abstract

Background: Most patients undergoing Transcatheter aortic valve implantation (TAVR) are elderly with significant co-morbidities and there is limited information available regarding factors that influence length of stay (LOS) post-procedure. The aim of this study was to identify the patient, and procedural factors that affect post-TAVR LOS using a contemporary multinational registry.

Methods: We conducted a retrospective cohort study, with patients recruited from three high volume tertiary institutions. The primary outcome was the LOS post-TAVR procedure. We examined patient and procedural factors in a cause-specific Cox multivariable regression model to elucidate their effect on LOS, accounting for the competing risk of post-procedural death. Hazard ratios (HR) greater than 1 indicate a shorter LOS, while HRs less than 1 indicate a longer LOS.

Results: The cohort consisted of 809 patients. Patient factors associated with longer LOS were older age, prior atrial fibrillation, and greater patient urgency. Patient factors associated with shorter LOS were lower NYHA class, higher ejection fraction and higher mean aortic valve gradients. Procedural characteristics associated with shorter LOS were conscious sedation (HR = 1.19, 95% CI 1.06–1.35, p = 0.004). Transapical access was associated with prolonged LOS (HR = 0.49, 95% CI 0.41–0.58, p < 0.001).

Conclusion: This multicenter study identified potentially modifiable patient and procedural factors associated with a prolonged LOS. Future research is needed to determine if interventions focused on these factors will translate to a shorter LOS.

Keywords: Transcatheter aortic valve replacement, Length of stay, Competing risks, Conscious sedation

Background

Aortic stenosis (AS) is the most frequent degenerative valvular heart disease in Western countries with a prevalence that has increased in parallel with the aging demographic of the population [1, 2]. AS patients are typically elderly with multiple co-morbidities, which precludes traditional surgical aortic valve replacement (SAVR) [3, 4]. Transcatheter aortic valve replacement (TAVR) has emerged over the last decade as an innovative procedure to deliver aortic valves percutaneously in a minimally invasive manner; based on landmark studies, guidelines now recommend TAVR as the preferred treatment for severe AS patients who are inoperable, and as a reasonable alternative in patients with high operative risk [5]. Emerging evidence supports the expansion of TAVR indications to intermediate risk patients [6]. As such, there has been an exponential growth in the demand for TAVR which will likely increase in the future.

Given the extensive pre-procedural diagnostic workup, the complexity of the prosthesis and procedure, and the requirement for close post-procedural follow-up, TAVR is extremely resource intensive [7–9]. Given the current economic environment, there is increasing need...
to improve the efficiency of health care delivery in complex interventions such as TAVR, in order to improve the overall value of health care and also improve equitable access to this life-saving intervention within strict budgetary constraints. One such area specific to TAVR is improving post-procedural length of stay (LOS). In addition to its economic benefits, optimizing LOS in an elderly population has a number of other potential clinical advantages such as reducing infection rates, increasing rehabilitation rates, avoiding malnutrition, and improving overall psychological status.

Although TAVR has been shown to have shorter hospitalizations compared to SAVR [10], some TAVR patients nonetheless have prolonged post-procedural stay [7, 11]. Moreover, there is a wide variation in reports of TAVR LOS reinforcing the likelihood of inefficient care. For example, some studies report the mean hospital stay following TAVR to be 11–13 days [7, 12], while other contemporary cohorts demonstrate hospitalization duration shorter than three days in approximately 30% of patients [11, 13, 14].

There is a paucity of data on the drivers that impact LOS post-TAVR. Elucidating these factors is important so as to identify potentially modifiable factors that can lead to quality improvement interventions to optimize LOS. To address this gap in knowledge, we sought to identify the major drivers of post-TAVR LOS using a contemporary multinational registry.

**Methods**

We conducted a retrospective cohort study, with patients recruited from three tertiary institutions, including two in Toronto, Canada (Sites 1 and 3) and one in Tel Aviv, Israel (Site 2). Research ethics board approval was obtained from all centers for the prospective databases. The need for individual patient consent was waived by all the institutional review boards.

**Patient selection**

Patients were identified from the TAVR registries from each institution. Each registry collects data on all TAVR patients prospectively. Inclusion criteria were all patients that had a TAVR procedure from January 1st, 2012 to December 31st, 2014. This time frame was chosen in order to include only patients receiving a contemporary TAVR valve procedure, and after each site completed at least 100 cases to overcome the learning curve associated with TAVR. We treated in-hospital death as a competing risk and included patients who died during the procedure or during the TAVR hospitalization.

**Outcome variable**

The primary outcome was the LOS post-TAVR procedure. The day of the TAVR was considered time 0, with each 24-h period after this recorded as 1 day. Additional outcomes of interest included peri-procedural minor and major complications, which were defined according to the Valve Academic Research Consortium (VARC- 2) criteria [15].

**Covariates**

We also documented the length of time (in days) patients were admitted prior to the TAVR procedure as well as the total LOS, from the date of admission to discharge from the TAVR hospital. For the purpose of analyses, we categorized pre-TAVR admission into 2 groups: a) those admitted electively up to two days prior to the procedure and b) those with a TAVR pre-admission of ≥3 days. This categorization was consistent with these hospitals’ clinical practice based on the advice of our clinical experts, as patients admitted ≥3 days pre-TAVR have pre-procedural clinical deterioration. We determined if the procedure was done 1 day prior to the weekend and contrasted these from procedures done earlier in the week. Patient characteristics that were abstracted from the registries included age, gender, body-mass index (BMI), co-morbidities, as well as mean gradient across the aortic valve.

Peri-procedural risk of in-hospital/30 day mortality was captured by the Society for Thoracic Surgery (STS) score [16, 17]. This score includes approximately 30 variables, including demographics, risk factors, previous interventions, pre-operative status, hemodynamics, and coronary anatomy, and has been well validated to accurately predict peri-operative mortality and morbidity.

Procedural factors included the access type, transcatheter heart valve type, conscious or general anesthesia, and procedural time. We also included the year of the procedure to account for temporal improvements in care delivery.

**Statistical analysis**

Data completeness was verified for all covariates and there were <1% missing data in any co-morbidity field with the exception of EuroScore [18]; as such a complete case analysis was conducted. Descriptive statistics were compared across the 3 hospitals for baseline data, procedure characteristics, and complications, with χ² tests for categorical variables and one-way analysis of variance (ANOVA) for continuous variables.

In order to identify the drivers of LOS, we developed a cause-specific Cox-proportional hazard model, where the dependent variable was the post-TAVR LOS, measured in days [19, 20]. In our study, this is analogous to modeling the rate (or hazard) of being discharged. Hazard ratios (HR) greater than 1 indicate a shorter LOS, while HRs less than 1 indicate a longer LOS. We built a cause-specific Cox model to account for the competing risk of
in-hospital death, which precludes the possibility of the primary outcome (discharge). The models included a sandwich type variance estimator to account for clustering of patients at each of the three institutions. We compared the unadjusted LOS between the 3 hospitals using this model.

Prior to inclusion into the final covariate-adjusted model, we assessed all baseline factors for co-linearity based on the variance inflation factor but found no important multi-colinearities. To build the final covariate adjusted model, we planned to include all variables except for EuroScore due to >5% missing data. The results for creatinine lacked face validity in the adjusted model so it was excluded. All other variables were included as this was an explanatory model. The proportional hazards assumption was tested by computing Martingale residuals for the final model.

A sensitivity analysis was conducted to understand the role of complications in TAVR post-procedural LOS. For each complication, we calculated both an unadjusted HR and one adjusted for all co-variates in the full model. All of the analyses were considered significant at a two-tailed p-value of less than 0.05. All analysis was done with SAS 9.3.

**Results**

We included a total of 809 patients from three centers over the time period of interest. Mean pre-TAVR LOS differed between the three sites. Site two routinely admitted elective patients one to two days before TAVR, while the other sites generally admitted these patients on the morning of the procedure (Table 1). Figure 1 demonstrates the post-TAVR LOS. Approximately 27.1% of patients had post-procedural LOS between 2 to 3 days. The three sites show no significant differences in terms of post-TAVR or total LOS. The mean post-procedural LOS was 6.6 days, with means of 6.9, 5.8 and 7.7 at the three sites, while mean total LOS was calculated at 8.8 days across sites, with site-specific values of 9.8, 7.9 and 9.4, respectively.

The incidence of complications for the entire cohort is summarized in Additional file 1: Table S1, as is post-procedure aortic regurgitation and post-procedure mitral regurgitation. Thirty patients (3.7%) died in hospital, while 30-day mortality was 4.9%. The rates of complications were comparable to those found in the literature, with 18 (2.2%) having a stroke, 107 (13.2%) requiring a permanent pacemaker, 49 (6.1%) suffering from a major vascular complication, and 37 (4.6%) having major bleeding.

As seen in Table 2, there was a temporal effect on LOS identified in the multivariable models, with patients undergoing TAVR in 2012 having a longer LOS compared to those in 2014. We found the following patient characteristics to be associated with longer length of stay: prior atrial fibrillation (HR = 0.76, 95% CI 0.69–0.84, p < 0.001), each one-year increase in patient age (HR = 0.990, 95% CI 0.985–0.995, p < 0.001), and patient urgency as indicated by pre-TAVR admission of three or more days (HR = 0.64, 95% CI 0.46–0.90, p = 0.009).

Patients were discharged sooner if they were NYHA class 1 or 2 (HR = 1.28, 95% CI 1.10–1.49, p = 0.001) or NYHA class 3 (HR =1.16, 95% CI 1.03–1.31, p = 0.019) compared to NYHA class 4. Every 10% increase in ejection fraction was associated with shorter length of stay (HR = 1.05, 95% CI 1.03–1.07, p < 0.001), as was each one mmHg increase in the pre-procedural mean aortic valve pressure gradient (HR = 1.004, 95% CI 1.002–1.01, p < 0.001). Patients who had at least one prior open heart surgery were also discharged sooner (HR = 1.15, 95% CI 1.09–1.21, p < 0.001).

Procedure factors had important impact on post-TAVR LOS. Patients receiving conscious sedation, rather than general anesthesia, had a significantly shorter LOS (HR = 1.19, 95% CI 1.06–1.35, p = 0.004). Compared to patients receiving TAVR via trans-femoral approach, direct aortic approach was associated with longer LOS (HR = 0.76, 95% CI 0.67–0.85, p < 0.001), as was trans-apical approach (HR = 0.49, 95% CI 0.41–0.58, p < 0.001). A subclavian or suprasternal approach was associated with earlier discharge compared to transfemoral (HR = 2.42, 95% CI 1.40–4.20, p = 0.002); however, there were few patients with these alternative access sites (n = 3) in our cohort. Longer TAVR procedure duration was associated with longer LOS (HR = 0.98 for every 10 min increase, 95% CI 0.96–0.99, p = 0.001). In terms of valve type, implantation of a Portico trans-catheter heart valve was associated with longer LOS (HR = 0.43, 95% CI 0.25–0.73, p < 0.001). A valve in valve procedure was associated with shorter LOS (HR = 1.28, 95% CI 1.15–1.41, p < 0.001).

The unadjusted HR suggest that almost all post procedure complications are statistically associated with longer LOS, except for new arrhythmia and myocardial infarction (p = 0.090, p = 0.055, respectively). When adjusted for baseline characteristics, all post-procedural complications were associated with a statistically significant increase in length of stay (Table 3).

**Discussion**

In this multi-center study of contemporary TAVR procedures, we found a wide variation in post-TAVR LOS. We identified a number of potentially modifiable factors that influenced LOS, such as access route, type of anesthesia, the timing of the procedure prior to the weekend, procedure time, and valve type. These are potential targets for quality improvement initiatives. Importantly, we found that post-procedural complications were strongly associated with prolonged stay.
Table 1 Baseline Patient and Procedural Characteristics. Cohort baseline and procedural characteristics according to site. All covariates are presented as frequencies and percentages, with the exception of mean values. Mean values include standard deviation.

| Patient Characteristics | Total (N = 809) | Site 1 (n = 164) | Site 2 (n = 406) | Site 3 (n = 239) | p Value |
|-------------------------|-----------------|-----------------|-----------------|-----------------|---------|
| Age (years)             | 82.7 ± 6.4      | 83.7 ± 6.4      | 82.4 ± 6.2      | 82.6 ± 6.7      | 0.095   |
| Female                  | 415 (51.3%)     | 79 (48.2%)      | 219 (53.9%)     | 117 (49.0%)     | 0.316   |
| BMI                     | 27.1 ± 5.3      | 27.0 ± 6.1      | 27.3 ± 5.3      | 26.6 ± 4.6      | 0.224   |
| STS                     | 6.0 ± 5.4       | 4.4 ± 2.8       | 4.3 ± 2.9       | 10.0 ± 7.6      | <0.001  |
| NYHA                    |                 |                 |                 |                 |         |
| 1                       | 2 (0.3%)        | 2 (1.2%)        | 0               | 0               |         |
| 2                       | 99 (12.3%)      | 15 (9.2%)       | 55 (13.6%)      | 29 (12.3%)      |         |
| 3                       | 505 (62.9%)     | 120 (73.6%)     | 227 (56.2%)     | 158 (67.0%)     | <0.001  |
| 4                       | 197 (24.5%)     | 26 (16.0%)      | 122 (30.2%)     | 49 (20.8%)      |         |
| Atrial Fibrillation     | 280 (34.6%)     | 68 (41.5%)      | 135 (33.3%)     | 77 (32.2%)      | 0.114   |
| Hypertension            | 717 (88.6%)     | 141 (86.0%)     | 358 (88.2%)     | 218 (91.2%)     | 0.245   |
| Diabetes Mellitus       | 279 (34.5%)     | 48 (29.3%)      | 155 (38.2%)     | 76 (31.8%)      | 0.075   |
| Dyslipidemia            | 645 (79.8%)     | 114 (69.5%)     | 333 (82.2%)     | 198 (82.9%)     | 0.001   |
| COPD                    | 129 (16.0%)     | 16 (9.8%)       | 55 (13.6%)      | 58 (24.3%)      | <0.001  |
| Coronary Artery Disease | 520 (64.3%)     | 87 (53.1%)      | 260 (64.0%)     | 173 (72.4%)     | <0.001  |
| Peripheral Vascular Disease | 93 (11.5%) | 24 (14.6%)      | 17 (4.2%)       | 52 (21.8%)      | <0.001  |
| Dialysis                | 26 (3.2%)       | 5 (3.1%)        | 10 (2.5%)       | 11 (4.6%)       | 0.328   |
| Permanent Pacemaker     | 101 (12.5%)     | 25 (15.2%)      | 55 (13.6%)      | 21 (8.8%)       | 0.103   |
| Prior Stroke            | 120 (14.8%)     | 35 (21.3%)      | 52 (12.8%)      | 33 (13.8%)      | 0.030   |
| Prior Cardiac Surgery   | 203 (25.1%)     | 46 (28.1%)      | 89 (21.9%)      | 68 (28.5%)      | 0.113   |
| Prior PCI               | 196 (24.2%)     | 32 (19.5%)      | 55 (13.6%)      | 109 (45.6%)     | <0.001  |
| Pre-Procedural Ejection Fraction (%) | 54.3 ± 10.7 | 51.7 ± 9.0 | 55.1 ± 8.6 | 54.5 ± 14.3 | 0.003 |
| Pre-Procedural Mean Pressure Gradient (mmHg) | 46.4 ± 15.9 | 48.8 ± 16.3 | 46.2 ± 15.0 | 45.2 ± 16.8 | 0.071 |
| Pre-Procedural Creatinine (μmol/L) | 107.9 ± 64.0 | 113.6 ± 88.9 | 104.0 ± 58.9 | 110.6 ± 50.5 | 0.203 |

Procedural Characteristics

| Procedure Year | Total (N = 809) | Site 1 (n = 164) | Site 2 (n = 406) | Site 3 (n = 239) | p Value |
|----------------|-----------------|-----------------|-----------------|-----------------|---------|
| 2012           | 224 (27.7%)     | 42 (25.6%)      | 129 (31.8%)     | 53 (22.2%)      | 0.015   |
| 2013           | 274 (33.9%)     | 66 (40.2%)      | 131 (32.3%)     | 77 (32.2%)      |         |
| 2014           | 311 (38.4%)     | 56 (34.2%)      | 146 (36.0%)     | 109 (45.6%)     |         |
| Procedure Prior to Weekenda | 185 (22.9%) | 2 (1.2%) | 26 (6.4%) | 157 (65.7%) | <0.001 |
| Procedure Time (min) | 161.1 ± 67.5 | 87.4 ± 38.8 | 168.9 ± 50.1 | 199.6 ± 69.7 | <0.001 |
| Access Site    |                 |                 |                 |                 | <0.001  |
| Transfemoral   | 737 (91.1%)     | 111 (67.7%)     | 405 (99.8%)     | 221 (92.5%)     |         |
| Subclavian     | 2 (0.3%)        | 0               | 1 (0.3%)        | 1 (0.4%)        |         |
| Suprasternal   | 1 (0.1%)        | 1 (0.6%)        | 0               | 0               |         |
| Direct Aortic  | 26 (3.2%)       | 10 (6.1%)       | 0               | 16 (6.7%)       |         |
| Transapical    | 43 (5.3%)       | 42 (25.6%)      | 0               | 1 (0.4%)        |         |
| Anesthesia Type |                 |                 |                 |                 | <0.001  |
| General Anesthesia | 408 (50.4%) | 164 (100%) | 5 (1.2%) | 239 (100%) |         |
| Local/Conscious Sedation | 401 (49.6%) | 0 | 401 (98.8%) | 0 |         |
Improving efficiency of health care delivery is of particular importance in the current era of budgetary constraints such that scarce health care resources are used optimally. One target for improving efficiency is reduction of LOS. Indeed, there is an abundant literature on LOS in different areas of medicine, specifically the drivers of prolonged LOS as well as strategies to improve it. For example, malnutrition measured by recent weight loss or a BMI below 20 has been associated with prolonged LOS [21]. Surgical site infections are a major driver of LOS in the surgical literature with a doubling of the LOS [22]. Early interventions and internal fixations have been associated with reduced LOS in patients with hip fractures [23]. Improving patients’ renal function [24] as well as pulmonary function have been associated with shorter LOS in patients undergoing cardiac surgery [25]. Increasing hospital volume has been associated with a reduced LOS [26]. Many of these factors are potentially modifiable and thus targets for quality improvement.

TAVR is an example of a complex intervention, targeted to an elderly patient population, often with multiple comorbidities. Moreover, it is extremely resource intensive, and in many jurisdictions, limited to select tertiary hospitals, each with limited funding. These supply factors,

| Valve Used                      | <0.001 |
|--------------------------------|--------|
| Medtronic CoreValve or Evolut R | 458 (56.7%) | 1 (0.6%) | 253 (62.6%) | 204 (85.3%) |
| Edwards XT or S3                | 332 (41.2%) | 155 (94.5%) | 146 (36.1%) | 31 (13%)    |
| Portico                         | 17 (0.2%) | 8 (4.9%) | 5 (1.2%) | 4 (1.7%)    |
| Valve in Valve                  | 34 (4.2%) | 8 (4.9%) | 0 | 26 (10.9%) | <0.001 |

Table 1 Baseline Patient and Procedural Characteristics. Cohort baseline and procedural characteristics according to site. All covariates are presented as frequencies and percentages, with the exception of mean values. Mean values include standard deviation (Continued)

BMI Body Mass Index, COPD Chronic Obstructive Pulmonary Disease, NYHA New York Heart Association functional classification, PCI percutaneous coronary intervention, STS Society of Thoracic Surgeons adult cardiac surgery risk score
*Refers to procedures that take place one day prior to the weekend

Fig. 1 Distribution of Post-TAVR Length of Stay of Discharged Patients. Figure shows percentage of patients discharged in each time period following TAVR. All patients have a minimum LOS of 2 days
combined with an exponentially growing demand, in particular as indications expand beyond only inoperable and very high risk patients, make TAVR an especially relevant area to identify potential targets for improving efficiency. The limited data on TAVR LOS currently suggests that there is variation in LOS [13, 27, 28].

In our study, we confirmed this wide variation in LOS, extending from 2 days to 59 days. We were able to identify a number of baseline patient characteristics that were associated with prolonged LOS, including prior atrial fibrillation, age, and lower baseline ejection fraction. Indeed, LOS appears to be a surrogate for the burden of co-morbidity. Although these factors are non-modifiable, they nonetheless should alert health care providers of the potential for a longer LOS, and as such, pre-emptive measures could be put into place early to facilitate transitions to the community or in-patient rehabilitation.

We also identified a number of potentially modifiable procedural factors such as procedure done before the weekend, valve type and conscious sedation. Indeed, other groups are evaluating the use of conscious sedation in combination with a care pathway to facilitate next day discharge post TAVR [29–31]. Conscious Sedation and non-surgical access have been associated with less delirium and might explain the shorter LOS. [32] The relationship between length of procedure and higher NYHA with LOS might be explained by the increased incidence of complications in sicker patients. Similarly, in hospital TAVI patients are more frail and await rehabilitation and hence have longer LOS. [33] The relationship between Portico valve and LOS might be attributed to a learning curve since it is a newer valve compared to Corevalve and Sapien valves. Longer LOS when the TAVR procedure is performed prior to the weekend has face validity and may be related to delays in obtaining post-procedural echocardiograms during the weekend, or being able to put into place the necessary transition supports such as homecare. If so,
this suggests that development of strategies to mitigate these delays; one such strategy could be performing echo-cardiography immediately post procedure. These are all potential areas for future study.

It is important to note the complex relationship between pre-procedural LOS and post-procedural hospitalization duration. We grouped patients admitted to hospital 0–2 days pre-TAVR as they likely received an elective TAVR. It is clear that elective pre-admission did not impact post-TAVR LOS. In contrast, patients who were admitted for longer periods prior to their TAVR likely represent patients who had decompensated heart failure. This group has a substantially longer LOS; this illustrates that once TAVR patients deteriorate while waiting for their procedure, this translates into a slower recovery post-procedure. This reinforces the importance of diligent wait-time management for TAVR patients.

In addition, there are some general measures that have been shown to help reduce LOS which might also be relevant to TAVR patients. Patients with expected long LOS might benefit from preemptive interventions [34, 35] including geriatric care and pre-procedural rehab [36, 37], nutrition supplementation [38], reducing bleeding risk [39], optimize periprocedural practice [29, 40, 41], and post procedural rehabilitation [42].

Our study provides a number of new insights to the literature. First, we used competing risk models to include all TAVR patients in our analyses, not only those who survived to discharge. This eliminates the potential biases introduced by only studying patients selected for survival. In addition, we have shown that in TAVR the occurrence of a post-procedural complication has a remarkable influence on LOS and one can hypothesize that the occurrence of complications may be one of the causal pathways by which the factors identified in our models impact LOS. The extended LOS likely explains in part the increased costs associated with complications [8, 39].

Our study must be interpreted in the context of several limitations that merit discussion. Although we had a relatively larger sample size across two countries, and used a clustered model to account for potential site related factors, our cohort was limited to three tertiary care hospitals that had wide variability in clinical practice (access site, sedation type, etc.), which impacts the generalizability of our findings. Second, although we identified factors associated with LOS, it does not follow necessarily that changing those factors will translate to shorter LOS. Instead, potential strategies impacting those factors must be empirically tested. Third, we did not have data on frailty or social status. The number of portico cases was small as were subclavian and direct aortic access routes and therefore, any conclusions regarding these variables may be explained by the learning curve. Finally, our study was an observational study, and there may have residual confounders that we did not account for. As such, our results should be considered hypothesis generating and not conclusive.

---

**Table 3** Relationship between Presence of Complication to Post-TAVR Length of Stay, with Unadjusted and Adjusted Analyses. Hazard ratios with 95% confidence intervals for post-TAVR LOS according to presence of different complications. Includes unadjusted analysis as well as multivariable adjustment for baseline and procedural characteristics.

| Type                | Unadjusted Hazard Ratio | p Value | Adjusted Hazard Ratio | p Value |
|---------------------|-------------------------|---------|-----------------------|---------|
| Vascular            |                         |         |                       |         |
| Major               | 0.46 (0.33–0.64)        | <0.001  | 0.42 (0.37–0.49)      | <0.001  |
| Minor               | 0.79 (0.64–0.97)        | 0.023   | 0.73 (0.58–0.93)      | 0.011   |
| Stroke              | 0.31 (0.19–0.50)        | <0.001  | 0.35 (0.22–0.55)      | <0.001  |
| MI                  | 0.33 (0.11–1.02)        | 0.055   | 0.6 (0.42–0.84)       | 0.003   |
| Arrhythmia          | 0.88 (0.76–1.02)        | 0.090   | 0.75 (0.61–0.93)      | 0.008   |
| Permanent Pacemaker | 0.59 (0.48–0.73)        | <0.001  | 0.49 (0.37–0.64)      | <0.001  |
| Bleeding            |                         |         |                       |         |
| Life Threatening    | 0.30 (0.17–0.55)        | <0.001  | 0.28 (0.17–0.46)      | <0.001  |
| Major               | 0.54 (0.38–0.76)        | <0.001  | 0.56 (0.46–0.68)      | <0.001  |
| Minor               | 0.69 (0.49–0.98)        | 0.036   | 0.82 (0.7–0.95)       | 0.009   |
| Transfusion         | 0.56 (0.46–0.68)        | <0.001  | 0.59 (0.54–0.65)      | <0.001  |
| Cardio-pulmonary bypass | 0.32 (0.12–0.87)  | 0.025   | 0.27 (0.18–0.41)      | <0.001  |
| Emergency operation | 0.31 (0.15–0.65)        | 0.002   | 0.31 (0.11–0.91)      | 0.033   |
| Open heart surgery  | 0.29 (0.09–0.89)        | 0.030   | 0.27 (0.18–0.41)      | <0.001  |
| Any Major Complication a | 0.44 (0.37–0.52)        | <0.001  | 0.38 (0.28–0.5)       | <0.001  |

Hazard ratios >1 indicate shorter time to discharge, while hazard ratios <1 indicate prolonged time to discharge. MI myocardial infarction

*Patient with any of the following complications: major vascular, stroke, MI, new permanent pacemaker, life-threatening bleeding, major bleeding, cardio-pulmonary bypass, emergency operation, or open heart surgery
Conclusions
In conclusion, this multicenter study identified a number of important modifiable patient and procedural factors associated with LOS. Future studies should evaluate if interventions focused on these potentially modifiable factors will translate to shorter LOS.

Additional file

Additional file 1: Table S1. Post-TAVR complications and select echo measurements of study cohort. (DOC 65 kb)

Abbreviations
AAS: Aortic Stenosis; CI: Confidence Interval; HR: Hazard ratio; LOS: Length of stay; NYHA: New York Heart association; STS: Society of Thoracic surgeons; TAVR: Transcatheter aortic valve replacement

Acknowledgements
NA.

Availability of data and material
The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request.

Funding
This study was funded in part by Schulich Heart Center and the Sunnybrook Research Institute. Dr. H. Wijeysundera is supported by a Distinguished Clinical Scientist Award from the Heart and Stroke Foundation of Canada. Dr. S. Frems is supported in part by the Bernard S. Goldman Chair in Cardiovascular Surgery. None of the funding bodies had any role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript. The authors take full responsibility for the manuscript.

Authors’ contributions
YA, NZ, DM, SR, SEF, ER, AC, SALN, AF, HCW were involved in the data acquisition and analysis. YA, NZ, DM, SR, SEF, ER, AC, SALN, AF, HCW were involved in the writing and/or collection, analysis, and interpretation of data and in writing the manuscript. All authors have read and approved the final version of the manuscript.

Competing interests
Dr. Wijeysundera receives research support from Edwards Lifesciences and Medtronic Inc. Dr. Radhakrishnan is a proctor for Medtronic Inc. Dr. Finkelstein is a proctor for Medtronic and Edwards Inc.

Consent for publication
Not applicable.

Ethics approval and consent to participate
All the datasets were approved by local ethics committees of each participating hospital: Sunnybrook Medical Centre (199–2013), St. Michael’s Hospital (12–270) and Tel Aviv medical Centre (0409–11). The need for individual patient consent was waived by all the institutional review boards.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Schulich Heart Centre, Division of Cardiology and Cardiac surgery, Sunnybrook Health Sciences Centre, Toronto, ON, Canada. 2University of Toronto, Toronto, ON, Canada. 3Institute for Clinical Evaluative Sciences (ICES), 2075 Bayview Avenue, Suite A202, Toronto, ON M4N 3M5, Canada. 4Sunnybrook Research Institute (SRI), Dept. of Medicine & Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada. 5St. Michael’s Hospital, Toronto, ON, Canada. 6Department of Cardiology, Tel Aviv Medical Center, Tel Aviv, affiliated to the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

References
1. Kampenidis V, Delgado V, van Mieghem NM, Kappetein AP, Leon MB, Bax JJ. Diagnosis and management of aortic valve stenosis in patients with heart failure. Eur J Heart Fail. 2016;18(5):469-81.
2. Nkomo VT, Gardin JM, Skelton TN, Gottliebson JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368:1005–11.
3. Reinholt J, Kaier K, Reinecke H, Schmoor C, Frankenstein L, Vach W, et al. Effect of Availability of Transcatheter Aortic-Valve Replacement on Clinical Practice. N Engl J Med. 2015;372:2438–47.
4. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363:1597–607.
5. Smith CR, Leon MB, Mack M, Miller DC, Moses JW, Svensson LG, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011;364:2197–88.
6. Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, et al. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med. 2016;372:1609–20.
7. Reinholt J, Kaier K, Gutmann A, Sorg S, von zur MC, Siepe M, et al. In-hospital resource utilization in surgical and transcatheter aortic valve replacement. BMC Cardiovasc Disord. 2015;15:132.
8. Gutmann A, Kaier K, Sorg S, von zur MC, Siepe M, Moser M, et al. Analysis of the additional costs of clinical complications in patients undergoing transcatheter aortic valve replacement in the German Health Care System. Int J Cardiol. 2015;179:231–7.
9. Barbanti M, Petronio AS, Ettori F, Labit A, Bedogni F, De Marco F, et al. 5-Year Outcomes After Transcatheter Aortic Valve Implantation With CoreValve Prosthesis. JACC Cardiovasc Interv. 2015;8:1084–91.
10. Minutello RM, Wong SC, Swaminathan RV, Feldman DN, Kaple RK, Horn EM, et al. Costs and in-hospital outcomes of transcatheter aortic valve implantation versus surgical aortic valve replacement in commercial cases using a propensity score matched model. Am J Cardiol. 2015;115(10):1443-7.
11. Noad RL, Johnston N, McKinley A, Dougherty M, Nzewi OC, Jeganathan R, et al. A pathway to earlier discharge following TAVI: Assessment of safety and resource utilization. Catheter Cardiovasc Interv. 2015. doi:10.1002/ccd.26005.
12. Gilard M, Ettchaninoff H, Iung B, Donzeau-Gouge P, Chevreul K, Fajadet J, et al. Registry of transcatheter aortic-valve implantation in high-risk patients. N Engl J Med. 2012;366:1705–15.
13. Durand E, Ettchaninoff H, Canville A, Bouzharn M, Godin M, Tron C, et al. Feasibility and safety of early discharge after percutaneous transcatheter aortic valve implantation with the Edwards SAPENT-XT prosthesis. Am J Cardiol. 2015;115:1116–22.
14. Barbanti M, Caprannazzo P, Ohno Y, Attizzani GF, Gulinio S, Imme S, et al. Early discharge after transcatheter aortic valve implantation. Heart. 2015;101:1485–90.
15. Kappetein AP, Head SJ, Genereux P, Piazza N, van Mieghem NM, Blackstone EH, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Thorac Cardiovasc Surg. 2013;145:S6–23.
16. Shahian DM, He X, Jacobs JP, Rankin JS, Welke KF, Filerado G, et al. The Society of Thoracic Surgeons Isolated Aortic Valve Replacement (AVR) Composite Score: a report of the STS Quality Measurement Task Force. Ann Thorac Surg. 2012;94:2166–71.
17. Shahian DM, He X, Jacobs JP, Rankin JS, Welke KF, Edwards FH, et al. The STS AVR+CABG composite score: a report of the STS Quality Measurement Task Force. Ann Thorac Surg. 2014;97:1604–9.
18. Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshev S, Salamon R. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg. 1999;16:9–13.
19. Konstantin M, Ben-Assa E, T Bio, Shacham Y, Zv-Baran T, Abramowicz Y, et al. Periprocedural bleeding, acute kidney injury, and long-term mortality after transcatheter aortic valve implantation. Can J Cardiol. 2015;31:56–62.
20. Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing Risk. J Am Stat Assoc. 1999;94:496–509.

Received: 4 October 2016 Accepted: 18 May 2017
Published online: 26 May 2017
21. van Vrooij LM, de Vos R, Borgmeijer-Hoelen MM, Haaring C, de Mol BA. Preoperative unintended weight loss and low body mass index in relation to complications and length of stay after cardiac surgery. Am J Clin Nutr. 2008;87:1656–61.

22. Kusachi S, Kashimura N, Konishi T, Shimizu J, Kusunoki M, Oka M, et al. Length of stay and cost for surgical site infection after abdominal and cardiac surgery in Japanese hospitals: multi-center surveillance. Surg Infect. 2012;13:257–65.

23. Buller LT, Best MJ, Quinnan SM. A Nationwide Analysis of Pelvic Ring Fractures: Incidence and Trends in Treatment, Length of Stay, and Mortality. Geriatr Orthop Surg Rehabil. 2016;7:9–17.

24. LaPar DJ, Rich JB, Isbell JM, Brooks CH, Crosby IK, Yarbora LT, et al. Preoperative Renal Function Predicts Hospital Costs and Length of Stay in Coronary Artery Bypass Grafting. Ann Thorac Surg. 2016;101:606–12.

25. Sasaki J, Dykes JC, Sosa LJ, Salvaggio JL, Tablante MD, Ojito J, et al. Risk Factors for Longer Hospital Stay Following the Fontan Operation. Pediatr Crit Care Med. 2016;17(5):411-9.

26. Shinjo D, Fushimi K. Preoperative factors affecting cost and length of stay for isolated off-pump coronary artery bypass grafting: hierarchical linear model analysis. BMJ Open. 2015;5:e008756.

27. Babaliaros V, Devireddy C, Lerakis S, Leonardi R, Iturra SA, Mavromatis K, et al. Comparison of transfemoral transcatheter aortic valve replacement performed in the catheterization laboratory (minimalist approach) versus hybrid operating room (standard approach): outcomes and cost analysis. JACC Cardiovasc Interv. 2014;7:898–904.

28. Serletis-Bizios A, Durand E, Cellier G, Tron C, Bauer F, Ginell B, Dacher JN, Cribier A, Eftchaninoff H. A Prospective Analysis of Early Discharge After Transfemoral Transcatheter Aortic Valve Implantation. Am J Cardiol. 2016;118(6):866-72. doi: 10.1016/j.amjcard.2016.06.035. Epub 2016 Jun 27.

29. Lauck SB, Wood DA, Achtem L, Baumbusch J, Boone RH, Cheung A, et al. Risk stratification and clinical pathways to optimize length of stay after transcatheter aortic valve replacement. Can J Cardiol. 2014;30:1583–7.

30. Wood DA, Poulter R, Cook R, Stub D, Leipsic JA, Ye J, et al. TCT-701 A Multidisciplinary, Multimodality, but Minimalist (3M) approach to transfemoral transcatheter aortic valve replacement facilitates safe next day discharge home in high risk patients: 1 year follow up. J Am Coll Cardiol. 2014;64

31. Lauck SB, Wood DA, Baumbusch J, Kwon JY, Stub D, Achtem L, et al. Vancouver Transcatheter Aortic Valve Replacement Clinical Pathway: Minimalist Approach: Standardized Care, and Discharge Criteria to Reduce Length of Stay. Clin Cardiovasc Qual Outcomes. 2016;9:312–21.

32. Abawi M, Nijhoff F, Agostoni P, Emmelot-Vonk MH, de Vries R, Movematis K, et al. Incidence, Predictive Factors, and Effect of Delirium After Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv. 2016;9:160–8.

33. Huded CP, Huded JM, Friedland JL, Benck LR, Lindquist LA, Holly TA, et al. Frailty Status and Outcomes After Transcatheter Aortic Valve Implantation. Am J Cardiol. 2016;117:1966–71.

34. Goodman H, Parsons A, Davison J, Preedy M, Peters E, Shuldham C, et al. A randomised controlled trial to evaluate a nurse-led programme of support and lifestyle management for patients awaiting cardiac surgery: ‘Fit for surgery: Fit for life’ study. Eur J Cardiovasc Nurs. 2008;7:189–95.

35. Arthur HM, Daniels C, McKelvie R, Hirsh J, Rush B. Effect of a preoperative intervention on preoperative and postoperative outcomes in low-risk patients awaiting elective coronary artery bypass graft surgery: A randomized, controlled trial. Ann Intern Med. 2014;160:305–13.

36. Oparisch C, Patrignani A, Mazz A, Gualco A, Cobelli F, Pinna GD. An elderly-centered, personalized, physiotherapy program early after cardiac surgery. Eur J Cardiovasc Prev Rehabil. 2010;17:50–7.

37. Fuzer G, Dumville JC, Mikes JN, Irvine K, Thompson DR, Leun RJ. “Prehabilitation” prior to CABS surgery improves physical functioning and depression. Int J Cardiovasc Nurs. 2009;13:351–8.

38. van Vrooij LM, de Vos R, Zijlstra E, Borgmeijer-Hoelen MM, van Leeuwen PA, de Mol BA. The impact of low preoperative fat-free body mass on infections and length of stay after cardiac surgery: a prospective cohort study. J Thorac Cardiovasc Surg. 2011;142:263–9.

39. Reinohl J, Gattellari A, Kollum M, von Zur M, Baumbach H, Avlar M, et al. Transfemoral aortic valve implantation: bleeding events, related costs and outcomes. J Thromb Thrombolysis. 2013;35:469–75.

40. Shuvy M, Mewa J, Wolff R, Hutson J, Austin PC, Bentley D, et al. Preprocedure Anemia Management Decreases Transfusion Rates in Patients Undergoing Transcatheter Aortic Valve Implantation. Can J Cardiol. 2015. doi: 10.1016/j.cjca.2015.08.018.